Overview
Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging
Status:
Completed
Completed
Trial end date:
2008-12-01
2008-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a study involving the use of Magnetic Resonance Imaging (MRI) contrast agents called Gadavist. The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Gadavist when used for taking images of the brain and spine. The results of the MRI will be compared to the results of images taken without Gadavist.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Bayer
Criteria
Inclusion Criteria:- Patients referred for contrast enhanced MRI of the CNS based on symptoms or previous
procedures.
Exclusion Criteria:
- Patients with acute renal insufficiency
- Patients with severe renal disease
- Patients with any contraindication to magnetic resonance imaging.